Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Nanobiotix ( (NBTX) ).
On May 21, 2026, Nanobiotix announced that trading of its ordinary shares on Euronext Paris would be temporarily halted from the market opening at 9:00 a.m. CEST at the company’s request. The halt is intended to facilitate allocation confirmation and pricing disclosure for a previously announced global offering combining a U.S. ADS public sale with an international placement of ordinary shares and pre-funded warrants to qualified investors.
The company said the suspension will remain in effect until it issues a new communication, with trading on Euronext Paris expected to resume later the same day at around 3:30 p.m. Paris time. The move underscores Nanobiotix’s efforts to manage capital-raising in an orderly fashion across its dual listings, with implications for liquidity and valuation as it advances its late-stage clinical pipeline.
The most recent analyst rating on (NBTX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The score is primarily constrained by weak financial fundamentals (ongoing losses, cash burn, and balance-sheet pressure including negative equity and higher leverage). Offsetting this are strong technical momentum (though extended) and a constructive earnings-call outlook emphasizing improved runway and multiple clinical catalysts, while valuation support is limited given negative earnings and no dividend.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-stage clinical biotechnology company developing physics-based therapeutic approaches for cancer and other major diseases. Founded in 2003 and headquartered in Paris with subsidiaries including Cambridge, Mass., the group holds more than 25 patent families across oncology, bioavailability and biodistribution, and central nervous system disorders, and is dual-listed on Euronext Paris and Nasdaq.
Average Trading Volume: 76,716
Technical Sentiment Signal: Buy
Current Market Cap: $2.08B
For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.